Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

OLAPARIB vs OLMESARTAN: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

OLAPARIB vs OLMESARTAN: Safety Overview

Metric OLAPARIB OLMESARTAN
Total FAERS Reports 18,274 2,228
Deaths Reported 5,496 77
Death Rate 30.1% 3.5%
Hospitalizations 3,471 1,096
Average Patient Age 62.3 yrs 68.9 yrs
% Female Patients 79.9% 52.8%
FDA Approval Date Aug 17, 2017 N/A
Manufacturer AstraZeneca Pharmaceuticals LP N/A
Route ORAL N/A
Marketing Status Discontinued N/A